Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 10/20 | 0.42 |
| ▸ | PPARD | Q03181 | 8/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201522 | 0.88 | PPARG (0.53) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL24209462 | 0.83 | PPARG (0.54) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL5802964 | 0.81 | PPARG (0.51) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL943063 | 0.81 | PPARG (0.58) | PPARGCYP3A4RXRAALDH1A1 | |
| SCHEMBL6509358 | 0.81 | PPARG (0.46) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL6509355 | 0.81 | PPARG (0.46) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL1162595 | 0.80 | LMNA (0.63) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL6383438 | 0.79 | PPARG (0.47) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL6383648 | 0.79 | PPARG (0.47) | PPARGCYP3A4RXRACYP4F2CYP4A11 | |
| SCHEMBL6383447 | 0.79 | PPARG (0.47) | PPARGCYP3A4RXRACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310367-A1 | A PROCESS FOR THE PREPARATION OF 4-Ý2-(5-ETHYL-2-PYRIDYL)ETHOXY¨NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.p.A. (IT) | 2011-04-20 | — | — | EP | claimed |
| US-20110046382-A1 | PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.P.A. (IT) | 2011-02-24 | — | — | US | claimed |
| WO-2009133576-A1 | A PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.P.A. (IT) | 2009-11-05 | — | — | WO | claimed |
| EP-2310367-A1 | A PROCESS FOR THE PREPARATION OF 4-Ý2-(5-ETHYL-2-PYRIDYL)ETHOXY¨NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.p.A. (IT) | 2011-04-20 | — | — | EP | disclosed |
| US-20110046382-A1 | PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
| WO-2009133576-A1 | A PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE | ERREGIERRE S.P.A. (IT) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046382-A1 | PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE | HNF4A, PPARA, CYP2E1 | PPARG 7/4885CYP3A4 11/4885RXRA 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.